Singapore Moves Upstream In The Medtech Value Chain
This article was originally published in Clinica
Singapore set out to build a knowledge-based economy some 25 years ago and biomedical sciences have been a key focus of successive five-year R&D funding initiatives. In this article exploring Singapore’s R&D landscape – including insights from key decision-makers and innovators – Tina Tan talks to executives of Exploit Technologies Pte Ltd. (ETPL), the commercialization arm of the country’s science and technology agency, A*STAR, on their models for engaging the different players in the innovation ecosystem. She also delves into one of Singapore’s research institutes, the Institute of Bioengineering and Nanotechnology, to find out what academia-industry collaborations are being forged there
You may also be interested in...
In a bid to expand the talent pool in its burgeoning medtech sector, Singapore has looked to the US West Coast – long regarded as a leading innovation hub in the global medtech arena – for ways to nurture a new generation of commercial-minded innovators. One such initiative is the Singapore-Stanford Biodesign (SSB) program, modelled after the renowned and successful Biodesign program at Stanford University. Tina Tan spoke to Ruey Feng Peh, director of SSB, to find out more about the program and what its outcomes have been to date.
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.